Prevail Therapeutics PRVL shares are trading higher on Thursday after the company reported it will highlight multiple gene therapy programs for neurodegenerative diseases at the 2020 Alzheimer's Association International Conference.
Prevail Therapeutics is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. Its pipeline products include PR001, PR006 and PR 004.
Prevail Therapeutics shares were trading up 6.01% at $16.37 on Thursday at the time of publication. The stock has a 52-week high of $19.96 and a 52-week low of $7.41.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
